Skip to main content
Log in

Effects of L-tryptophan treatment on central indoleamine metabolism and short-lasting neurologic disturbances in multiple sclerosis

  • Short Communications
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

Twelve MS patients were treated with L-tryptophan with or without decarboxylase inhibitor for 30 days, and the daily dose was either 1.5 g or 8 g. Tryptophan, 5-HIAA and HVA were analysed from lumbar punctures before and during tryptophan treatment. Clinical evaluation of MS symptoms was performed before, during and at the end of the tryptophan treatment period as well as after a 30-day placebo period. Tryptophan and 5-HIAA levels were found to be elevated 10 hours after the last dose of L-tryptophan. HVA concentrations remained approximately constant. A slight alleviation of changeable MS symptoms was noticed during the first month. The best response was found in symptoms like motility and bladder disturbances as well as in the mood of patients. These findings are indicative of the neural transmission changes during the rapid functional disturbances in MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Andén, N.-E., B. E. Roos, andB. Werdinius: On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. Life Sci.7, 448–458 (1963).

    PubMed  Google Scholar 

  • Ashcroft, G. W., andD. F. Sharman: Drug-induced changes in the concentration of 5-OR indolyl compounds in cerebrospinal fluid and caudate nucleus. Brit. J. Pharmacol.19, 153–160 (1962).

    PubMed  Google Scholar 

  • Barashi, S., andM. H. T. Roberts: The action of 5-hydroxytryptamine antagonists and precursors on bulbospinal facilitation of spinal reflexes. Brain Res.52, 385–388 (1973).

    PubMed  Google Scholar 

  • Carnegie, P. R.: Properties, structure, and possible neuroreceptor role of the encephalitogenic protein of human brain. Nature229, 25–28 (1971).

    PubMed  Google Scholar 

  • Carroll, B. J.: Monoamine precursors in the treatment of depression. Clin. Pharmacol. Therap.12, 743–761 (1971).

    Google Scholar 

  • Claveria, L. E., G. Curzon, M. J. G. Harrison, andB. D. Kantamaneni: Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis. J. Neurol. Neurosurg. Psychiat.37, 715–718 (1974).

    PubMed  Google Scholar 

  • Eccleston, D., G. W. Ashcroft, T. B. B. Crawford, J. B. Stanton, D. Wood, andP. H. McTurk: Effect of tryptophan administration on 5-HIAA in cerebrospinal fluid in man. J. Neurol. Neurosurg. Psychiat.33, 269 to 272 (1970).

    Google Scholar 

  • Harrer, G., andR. Fischbach: Über die Wirkung bestimmter Aminosäuren auf das Ergebnis des Überwärmungstests bei Multiple-Sklerose-Kranken. J. Neural Transmission34, 205–214 (1973).

    Google Scholar 

  • Hyyppä, M. T., D. Cardinali, H. Baumgarten, andR. J. Wurtman: Rapid accumulation of H3-serotonin in brain of rats receiving intraperitoneal H3-tryptophan: Effects of 5, 6-dihydroxytryptamine or female sex hormones. J. Neural Transmission34, 111–124 (1973).

    Google Scholar 

  • Johansson, B., andB.-E. Roos: 5-hydroxyindoleacetic acid in cerebrospinal fluid of patients with neurological diseases. Europ. Neurol.11, 37–45 (1974).

    PubMed  Google Scholar 

  • Knott, P. J., andG. Curzon: Free tryptophan in plasma and brain tryptophan metabolism. Nature239, 452–453 (1972).

    PubMed  Google Scholar 

  • Kurtzke, J. F.: Neurologic impairment in multiple sclerosis and disability status scale. Acta Neurol. Scand.46, 493–512 (1970).

    PubMed  Google Scholar 

  • Lennon, V. A., andP. R. Carnegie: Immunopathological disease: A break in tolerance to receptor sites. LancetI, 630–633 (1971).

    Google Scholar 

  • Mac Alpine, D., C. E. Lumsden, andE. D. Acheson: Multiple sclerosis: A reappraisal. Edinburgh-London: Livingstone. 1965.

    Google Scholar 

  • Miley, C. E., andF. M. Forster: Paroxysmal signs and symptoms in multiple sclerosis. Neurology (Minneap.)24, 458–461 (1974).

    Google Scholar 

  • van Praag, H. M., F. Flentge, J. Korf, L. C. W. Dols, andT. Schut: The influence of probenecid on the metabolism of serotonin, dopamine and their precursors in man. Psychopharmacologia (Berl.)33, 141–151 (1973).

    Google Scholar 

  • Sonninen, V., P. Riekkinen, andU. K. Rinne: Acid monoamine metabolites in cerebrospinal fluid in multiple sclerosis. Neurology23, 760–763 (1973).

    PubMed  Google Scholar 

  • Tourtelotte, V. W.: Cerebrospinal fluid in multiple sclerosis. In: Handbook of Clinical Neurology, Vol. 9, pp. 324–382. 1970.

    Google Scholar 

  • Wurtman, R. J., andJ. D. Fernstrom: Tryptophan, L-tyrosine and the control of brain monoamine biosynthesis. In: Perspectives in Neuropharmacology, pp. 143–193. New York: 1972.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hyyppä, M.T., Jolma, T., Riekkinen, P. et al. Effects of L-tryptophan treatment on central indoleamine metabolism and short-lasting neurologic disturbances in multiple sclerosis. J. Neural Transmission 37, 297–304 (1975). https://doi.org/10.1007/BF01258656

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01258656

Keywords

Navigation